Ocera Therapeutics (OCRX)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

555 TWIN DOLPHIN DRIVE REDWOOD CITY, CA 94065

Tranzyme is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel, first-in-class small molecule therapeutics for the treatment of acute (hospital-based) and chronic gastrointestinal (GI) motility disorders. GI motility disorders are conditions which disrupt the normal movement of food throughout the GI tract. Tranzymes two most advanced product candidates, ulimorelin, which is in Phase 3, and TZP-102, which is entering Phase 2b, are being evaluated for the treatment of predominantly upper GI motility disorders. Approximately 20 percent of adults worldwide are affected by conditions these product candidates are designed to treat. While upper GI motility disorders are a highly prevalent group of persistent and recurring conditions, there are currently a limited number of treatment options for patients suffering from these conditions. In addition to ulimorelin and TZP-102, Tranzyme is also developing a motilin antagonist, TZP-201, for the treatment of various forms of moderate-to-severe diarrhea, and a ghrelin antagonist, TZP-301, for the treatment of obesity and other metabolic diseases.

View SEC Filings from OCRX instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding OCRX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding OCRX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

VANLENT ANNE

  • Director
0 2017-12-11 0

KJELLSON NINA S

  • Director
0 2017-12-11 0

WEBER ECKARD

  • Director
0 2017-12-11 0

GRAIS LINDA S PRESIDENT AND CEO

  • Officer
  • Director
0 2017-12-11 0

WIERENGA WENDALL

  • Director
0 2017-12-11 0

JAMES STEVEN P

  • Director
0 2017-12-11 0

BYRNES MICHAEL CFO AND TREASURER

  • Officer
0 2017-12-11 0

BUKOFZER STAN CHIEF MEDICAL OFFICER

  • Officer
0 2017-12-11 0

DERE WILLARD H

  • Director
0 2017-12-11 0

DOMAIN PARTNERS VIII, L.P.

BLAIR JAMES C

DOVEY BRIAN H

TREU JESSE I

VITULLO NICOLE

HALAK BRIAN K

  • 10% Owner
No longer subject to file 2017-12-11 0

DP VIII ASSOCIATES, L.P.

BLAIR JAMES C

DOVEY BRIAN H

TREU JESSE I

VITULLO NICOLE

HALAK BRIAN K

  • 10% Owner
No longer subject to file 2017-12-11 0

DOMAIN PARTNERS VI, L.P.

BLAIR JAMES C

DOVEY BRIAN H

TREU JESSE I

VITULLO NICOLE

  • 10% Owner
No longer subject to file 2017-12-11 0

DP VI ASSOCIATES, L.P.

BLAIR JAMES C

DOVEY BRIAN H

TREU JESSE I

VITULLO NICOLE

  • 10% Owner
No longer subject to file 2017-12-11 0

DOMAIN ASSOCIATES

BLAIR JAMES C

DOVEY BRIAN H

TREU JESSE I

VITULLO NICOLE

HALAK BRIAN K

KAMDAR KIM P.

  • 10% Owner
No longer subject to file 2017-12-11 0

THOMAS MCNERNEY & PARTNERS LP

TMP ASSOCIATES LP

TMP NOMINEE, LLC

THOMAS, MCNERNEY & PARTNERS, LLC

THOMAS, MCNERNEY & PARTNERS II L.P.

TMP ASSOCIATES II LP

TMP NOMINEE II, LLC

THOMAS, MCNERNEY & PARTNERS II, LLC

THOMAS JAMES E

  • 10% Owner
No longer subject to file 2017-01-30 0

POWELL MICHAEL

  • Director
0 2016-12-31 0

AGGARWAL GAURAV CHIEF BUSINESS OFFICER

  • Officer
20,000 2016-01-15 0

PATNI RAJIV CHIEF DEVELOPMENT OFFICER

  • Officer
5,050 2015-05-07 0

SHAH NIMESH

  • 10% Owner
47,963 2015-01-01 0

TETLOW SHARON ACTING CFO & TREASURER

  • Officer
3,000 2014-07-11 0

CASTAIGNE JEAN-PAUL

  • Director
0 2014-06-11 0

EKMAN LARS

  • Director
0 2014-06-11 0

SOFINNOVA VENTURE PARTNERS VI L P

SOFINNOVA VENTURE PARTNERS VI GMBH & CO. KG

SOFINNOVA VENTURE AFFILIATES VI LP

SOFINNOVA MANAGEMENT VI, L.L.C.

BUATOIS ERIC

AZAN ALAIN

HEALY JAMES

  • 10% Owner
No longer subject to file 2014-03-18 0

ROUSSEAU FRANCK CHIEF MEDICAL & DEV OFFICER

  • Officer
  • Director
0 2013-12-19 0

SHAH PRATIK

  • Director
0 2013-12-19 0

HILLEMAN JERYL L CFO AND SECRETARY

  • Officer
0 2013-12-19 0

ZISSON ALEX

  • FORMERLY A DIRECTOR
No longer subject to file 2013-07-15 0

DOMAIN PARTNERS VIII, L.P.

  • 10% Owner
988,285 2013-07-15 0

DP VIII ASSOCIATES, L.P.

  • 10% Owner
7,333 2013-07-15 0

DOMAIN PARTNERS VI, L.P.

  • 10% Owner
1,565,463 2013-07-15 0

DP VI ASSOCIATES, L.P.

  • 10% Owner
15,731 2013-07-15 0

DOMAIN ASSOCIATES

  • 10% Owner
47,963 2013-07-15 0

DOVEY BRIAN H

  • 10% Owner
1,629,157 2013-07-15 0

BLAIR JAMES C

  • 10% Owner
1,588,857 2013-07-15 0

TREU JESSE I

  • 10% Owner
1,629,157 2013-07-15 0

SCHOEMAKER KATHLEEN K

  • 10% Owner
1,629,157 2013-07-15 0

VITULLO NICOLE

  • 10% Owner
1,629,157 2013-07-15 0

HALAK BRIAN K

  • 10% Owner
1,629,157 2013-07-15 0

KAMDAR KIM P.

  • 10% Owner
47,963 2013-07-15 0

MCGOWAN DANA S. CFO AND SECRETARY

  • Officer
0 2013-07-15 0

THOMAS, MCNERNEY & PARTNERS II L.P.

TMP NOMINEE II, LLC

TMP ASSOCIATES II LP

THOMAS, MCNERNEY & PARTNERS II, LLC

  • 10% Owner
2,438,569 2013-07-15 0

THOMAS MCNERNEY & PARTNERS LP

TMP NOMINEE, LLC

TMP ASSOCIATES LP

THOMAS, MCNERNEY & PARTNERS, LLC

THOMAS JAMES E

MCNERNEY PETE

ZISSON ALEX

SHAH PRATIK

AGUIAR ERIC

  • Director
  • 10% Owner
2,438,569 2013-07-15 0

THOMAS, MCNERNEY & PARTNERS II L.P.

TMP NOMINEE II, LLC

TMP ASSOCIATES II LP

AGUIAR ERIC

  • 10% Owner
2,438,569 2013-07-15 0

STANLEY RHONDA L. CONTROLLER

  • Officer
0 2013-01-04 0

EISENSTADT RICHARD I VP, FINANCE & CFO

  • Officer
0 2012-08-07 0

THOMAS HELMUT SENIOR VP, R&D

  • Officer
0 2012-08-07 0

JOHNSON JOHN

  • Director
0 2012-08-07 0

GARG VIPIN K PRESIDENT & CEO

  • Officer
  • Director
0 2012-08-07 0

DAVIDSON AARON

  • Director
0 2012-08-07 0

ABERCROMBIE GEORGE B

  • Director
0 2012-08-07 0

MOORE DAVID VP, COMMERCIAL OPERATIONS

  • Officer
0 2012-04-19 0

14159 CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
57,704 2012-03-12 0

BAKER BROTHERS LIFE SCIENCES CAPITAL (GP), LLC

BAKER FELIX

BAKER JULIAN

  • 10% Owner
2,328,863 2012-03-12 0

BAKER BIOTECH CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
232,011 2012-03-12 0

KOSUTIC GORDANA VP, CLINICAL AND REGULATORY

  • Officer
0 2011-04-19 0

GAVIN BRENDA D

  • Director
0 2011-04-19 0

QUAKER BIO VENTURES LP

QUAKER BIOVENTURES CAPITAL LP

GAVIN BRENDA D

  • Director
  • 10% Owner
2,564,791 2011-04-06 0

THOMAS MCNERNEY & PARTNERS LP

TMP NOMINEE, LLC

TMP ASSOCIATES LP

THOMAS, MCNERNEY & PARTNERS, LLC

THOMAS JAMES E

MCNERNEY PETE

ZISSON ALEX

  • Director
  • 10% Owner
8,986,358 2011-04-06 0

CAPITAL REGIONAL ET COOPERATIF DESJARDINS

DESJARDINS-INNOVATECH S.E.C.

  • 10% Owner
No longer subject to file 2011-04-06 0

H.I.G. VENTURES - TRANZYME, LLC

HIG GP II INC

MNAYMNEH SAMI

TAMER ANTHONY

DAVIDSON AARON

  • Director
  • 10% Owner
3,002,291 2011-04-06 0

BDC CAPITAL INC.

  • 10% Owner
No longer subject to file 2011-04-06 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments